Introduction
Materials and methods
Study design
Patient population
Severity of condition
Randomization
Intervention
Micronutrient | Days 1 and 2 | Days 3–5 |
---|---|---|
Zinc, mg | 60 | 30 |
Selenium, μg | 540.4 | 270.2 |
Vitamin C, mg | 2,700a | 1,600a |
Vitamin B1, mg | 305a | 102.5 |
Vitamin E enteral, mg | 600 | 300 |
Vitamin E iv, mg | 12.8 | 6.4 |
Outcome variables
Laboratory determinations
Nutritional support
Blood glucose control
Statistical analysis
Results
Variable | All | Complex cardiac surgery | Trauma | Subarachnoid hemorrhage | ||||
---|---|---|---|---|---|---|---|---|
Number | 200 | 113 | 66 | 21 | ||||
AOX | Placebo | AOX | Placebo | AOX | Placebo | AOX | Placebo | |
Number | 102 | 98 | 57 | 56 | 34 | 32 | 11 | 10 |
Gender, male/female | 127/73 | 70/43a | 52/14a | 5/16a | ||||
Age, years | 59 ± 19 | 70 ± 10a | 40 ± 19a | 54 ± 9 | ||||
58 ± 19 | 59 ± 20 | 69 ± 8 | 71 ± 11 | 40 ± 19 | 40 ± 19 | 54 ± 7 | 53 ± 10 | |
Weight, kg | 74 ± 15 | 75 ± 16 | 75 ± 13 | 68 ± 12 | ||||
74 ± 15 | 74 ± 15 | 75 ± 16 | 74 ± 17 | 72 ± 12 | 77 ± 13b | 72 ± 13 | 64 ± 9c | |
Body mass index, kg/m2 | 25.8 ± 4.6 | 26.5 ± 5.0 | 24.9 ± 3.9 | 24.5 ± 3.4 | ||||
25.8 ± 4.8 | 25.7 ± 4.3 | 26.7 ± 5.3 | 26.2 ± 4.7 | 24.2 ± 3.8 | 25.6 ± 3.9 | 25.2 ± 4.0 | 23.7 ± 2.5 | |
SAPS II | 37.5 ± 12.7 | 39.3 ± 10.4d | 35.7 ± 15.4d | 33.9 ± 13.6d | ||||
38.4 ± 12.7 | 36.6 ± 12.8 | 38.4 ± 9.3 | 40.3 ± 11.4 | 39.9 ± 17.0 | 31.1 ± 12.2e | 33.6 ± 12.0 | 34.2 ± 9 | |
SOFA score at admission | 8.3 ± 2.5 | 9.1 ± 1.7a | 7.5 ± 3.1a | 6.3 ± 2.9a | ||||
8.2 ± 2.8 | 8.3 ± 2.2 | 8.8 ± 1.7 | 9.3 ± 1.6 | 7.8 ± 3.5 | 7.1 ± 3.2 | 5.7 ± 3.8 | 6.9 ± 1.4 |
Trauma (n = 66) | AOX | Placebo | P value |
---|---|---|---|
Number | 34 | 32 | |
Injury Severity Score, all | 30.1 ± 9.8 | 28.3 ± 10.4 | NS |
Brain injury (n = 39; 20/19) | 31.0 ± 11.0 | 28.7 ± 11.9 | NS |
No brain injury (n = 27; 14/13) | 28.9 ± 7.9 | 27.6 ± 8.1 | NS |
Injury Severity Score brain, in brain-injured | 14.5 ± 4.9 | 10.8 ± 4.5 | 0. 019 |
Glasgow Coma Scale score initial, all | 10.4 ± 4.9 | 11.8 ± 4.3 | 0.16 |
Brain injury | 7.4 ± 4.3 | 9.7 ± 4.8 | 0.11 |
No brain injury | 14.6 ± 0.6 | 14.8 ± 0.8 | NS |
SAPS II | 39.9 ± 17.0 | 31.1 ± 12.2 | 0.04 |
SOFA score, neuro section | 1.62 ± 1.7 | 0.97 ± 1.2 | 0.085 |
Brain injury | 2.5 ± 1.6 | 1.38 ± 1.2 | 0.012 |
No brain injury | 0.2 ± 0.4 | 0.2 ± 0.6 | NS |
Protocol violations
Outcome variables
Kidney function
Variable | All | Cardiac surgery | Trauma | |||
---|---|---|---|---|---|---|
AOX | Placebo | AOX | Placebo | AOX | Placebo | |
Number | 200 | 113 | 66 | |||
Number | 102 | 98 | 57 | 56 | 34 | 32 |
Prior renal failure | 61 (30.5%) | 49 (43.4%)a | 10 (15.1%) | |||
25 | 36 | 20 | 29 | 6 | 4 | |
Acute kidney injury | 66 (33%) | 50 (44.2%)a | 13 (19.7%) | |||
29 (30%) | 36 (37%) | 21 (37%) | 29 (52%)b | 7 | 6 | |
ARF increase of 50 μmol/L | 32 (16%) | 29 (27.5%)a | 3 (15.2%) | |||
15 (15%) | 17 (17% | 13 (23% | 16 (29%) | 2 | 1 | |
ARF increase of 90 μmol/L | 16 (8%) | 15 (13.3%)a | 1 (1.5%) | |||
7 (7%) | 9 (9%) | 6 (11% | 9 (16%) | 1 | 0 | |
CVVH | 7 (3.5%) | 6 (5.3%) | 1 (1.5%) | |||
6 | 1c,d | 5 | 1 | 1 | 0 | |
Persistent renal failure | 11 (5.5%) | 10 (8.8%) | 1 (1.5%) | |||
4 (4%) | 7 (7%) | 3 (5%) | 7 (13%)e | 1 | 0 | |
Ventilator-free days | 26.3 ± 5.5 | 26.6 ± 5.3 | 25.2 ± 6.3 | |||
26.1 ± 5.7 | 26.6 ± 5.2 | 25.9 ± 6.7 | 27.3 ± 3.3e | 25.5 ± 4.6 | 24.9 ± 7.7 | |
Infections (patients with) | 70 | 30 | 30 | |||
36 | 34 | 14 | 16 | 17 | 13 | |
Infectious episodes | 91 | 39 | 39 | |||
45 | 46 | 19 | 20 | 21 | 18 | |
Pneumonia episodes | 30 | 16 | 14 | |||
14 | 16 | 7 | 9 | 7 | 7 | |
Length of stay, days | ||||||
In the ICU | 5.6 ± 5.5 | 5.2 ± 5.1 | 6.3 ± 6.5 | |||
5.8 ± 5.4 | 5.4 ± 5.7 | 5.8 ± 6.0 | 4.7 ± 4.0 | 5.8 ± 4.4 | 6.8 ± 8.3 | |
In intermediate care | 5.0 ± 5.5 | 3.6 ± 3.5 | 6.5 ± 7.2 | |||
4.5 ± 4.9 | 5.5 ± 6.0 | 3.3 ± 4.2 | 3.4 ± 4.1 | 5.9 ± 7.1 | 7.1 ± 7.4 | |
In the hospital | 24 ± 20 | 19 ± 13 | 32 ± 22 | |||
23 ± 20 | 26 ± 20 | 20 ± 14 | 19 ± 13 | 26 ± 19 | 39 ± 24f | |
Deaths | ||||||
In the ICU | 14 (7%) | 11 (9.7%) | 2 (3%) | |||
8 | 5 | 6 | 5 | 2 | 0g | |
In hospital | 23 (11.5%) | 12 (10.6%) | 8 (12.1%) | |||
14 | 9 | 8 | 6 | 6 | 2g | |
At 3 months | 25 (12.5%) | 16 (14.2%) | 8 (12.1%) | |||
14 | 11 | 8 | 8 | 6 | 2g |
Sequential organ failure assessment scores
Infections and pneumonia
Length of mechanical ventilation
All | Day 0 | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 |
---|---|---|---|---|---|---|
AOX | 49 (0–2,350) | 129 (2–359)a | 161 (2–364)a | 125 (150–399)a,b | 100 (16–401)b | 80 (14–401) |
Placebo | 35 (2–176) | 141 (2–341)a | 174 (2–410)a | 156 (2–360)a,b | 114 (2–438)b | 82 (3–388) |
Cardiac surgery | ||||||
AOX | 59 (2–150) | 150 (2–359)a | 165 (2–317)a | 123 (20–367)a | 84 (20–319)b | 81 (14–243) |
Placebo | 39 (2–176) | 142 (37–341)a | 177 (53–410)a | 158 (44–360)a | 117(26–225)b | 81 (19–178) |
Trauma | ||||||
AOX | 35 (2–158) | 126 (4–282)a,b | 164 (9–464)a | 146 (41–399)a | 146 (41–282)a | 114 (41–282)a |
Placebo | 32 (2–224) | 147 (5–327)a,b | 201 (46–326)a | 174 (34–328)a | 161 (21–438)a | 117 (34–388)a |
Subarachnoid hemorrhage | ||||||
AOX | 32 (0–230) | 38 (3–277) | 42 (15–184) | 67 (16–103) | 44 (16–401) | 29 (8–401) |
Placebo | 10 (2–61) | 27 (2–185) | 22 (2–179) | 16 (2–233) | 22 (2–233) | 21 (2–163) |
Length of stay
Mortality
Biological variables
Trace elements and glutathione peroxidase
Plasma C-reactive protein
Glucose control
Insulin requirements
Nutritional support
Short Form 36-item health survey
Discussion
Rationale for the micronutrient doses and combinations
Study limitations
Conclusion
Key messages
-
This study confirms that the antioxidant micronutrient status is altered on admission in critically ill patients with organ failure.
-
Antioxidant supplements delivered intravenously for 5 days correct the initial alterations and restore antioxidant defenses, particularly the glutathione peroxidase activity.
-
There is no impact on organ failures (sequential organ failure assessment) during the first 5 days of admission, but a shorter hospital stay in trauma patients.
-
The supplements achieve blunting of the inflammatory response in diagnostic categories with severe systemic inflammatory response syndrome.